BioCentury
ARTICLE | Financial News

NMD raises €38M series A

March 22, 2018 8:49 PM UTC

NMD Pharma ApS (Aarhus, Denmark) raised €38 million ($46.6 million) in a tranched series A round led by new investor INKEF. Fellow new investor Roche Venture Fund and existing investors Novo Seeds and Lundbeckfonden Emerge also participated.

The company is developing inhibitors against chloride voltage-gated channel 1 (CLCN1; CLC1), which is specific to skeletal muscle fibers and inhibits nerve-to-muscle communication at the neuromuscular junction (see BioCentury, June 23, 2016)...

BCIQ Company Profiles

NMD Pharma A/S